Bio

I am a life-science business leader with global experience in scientific research, R&D management, company foundation and start-up development. As a scientist I published 50+ peer-reviewed research publications and delivered 50+ scientific presentations at scientific conferences and work has been cited over 1600 times. As a founder of Omixon I lead the company with strong genomic data analysis skills to the market niche of immunogenetics, developed the business model, led the licensing from the Children’s Hospital of Philadelphia, and thus established the foundation of a first-in-class and best-in-class human leukocyte antigen diagnostic test using next generation DNA sequencing. Omixon is a leader in HLA typing by next generation sequencing today. I am passionate about new molecular diagnostics product development where the challenge involves the combination of IP strategy, licensing, market research, competitive analysis and technology development. I was inspired to pursue entrepreneurship at the National Research Council (Canada), where I experienced the formation of 48 spin-off companies with funding over $300M in the 1990s. In Canada, my research supported a group of scientists whose decade-long effort lead to a carbohydrate vaccine saving lives of children. I believe that there are unexplored opportunities to commercialize great scientific results from academic labs. Currently several academic results in immunotherapy of cancer have great potential. As a former computational scientist, I believe in the value of algorithms not only in diagnostics but also in therapies. As we move to personalized or precision medicine, sophisticated proprietary algorithms become key source of competitive advantage. Contact me about commercialization opportunities of biomarkers or diagnostics.